61 85

Cited 1 times in

Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer

Authors
 Ji Ye Jung  ;  Eun Young Kim  ;  Arum Kim  ;  Joon Chang  ;  Nam Hoon Kwon  ;  Youngji Moon  ;  Eun Joo Kang  ;  Jun Sik Sung  ;  Hyunbo Shim  ;  Sunghoon Kim  ;  Yoon Soo Chang 
Citation
 Journal of Cancer, Vol.8(8) : 1347-1354, 2017 
Journal Title
 Journal of Cancer 
Issue Date
2017
Keywords
Aminoacyl t-RNA synthetase (ARS) ; Aminoacyl t-RNA synthetase-interacting multi-functional protein 2 (AIMP2) ; Aminoacyl t-RNA synthetase-interacting multi-functional protein 2-exon 2 deletion (AIMP2-DX2) ; Autoantibody ; Lung cancer.
Abstract
Aminoacyl-tRNA synthetase-interacting multi-functional protein 2 (AIMP2) works as potent tumor suppressor, while its splicing variant lacking exon 2 (AIMP2-DX2) competes with AIMP2 for binding to target proteins and compromises its anti-tumor activity. Assuming that AIMP2 and its variant AIMP2-DX2 could be released out to human sera in pathological condition, we investigated the diagnostic and prognostic usefulness of autoantibodies against AIMP2 and AIMP2-DX2 by measuring their serum levels in 80 normal and lung cancer samples that were matched in age, gender and smoking status. The area under the curve of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 autoantibody ratio was low (0.416, 0.579, and 0.357, respectively), suggesting limited diagnostic value. A total of 165 lung cancer patients were classified into low and high AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 based on the median expression of each parameter. The high AIMP2-DX2 group was older and had larger tumors (>3 cm) than the low AIMP2-DX2 group. The high AIMP2-DX2/AIMP2 group had higher CYFRA-21 levels and significantly shorter overall survival than the low AIMP2-DX2/AIMP2 group (18.6 vs. 48.9 months, P = 0.021, Log Rank Test). Taken together, autoantibodies against AIMP2-DX2 and AIMP2 are detectable in the human blood and the increased ratio of AIMP2-DX2/AIMP2 is related to poor clinical outcome of lung cancer.
Files in This Item:
T201701412.pdf Download
DOI
10.7150/jca.18450
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
김은영(Kim, Eun Young) ORCID logo https://orcid.org/0000-0002-3281-5744
장윤수(Chang, Yoon Soo) ORCID logo https://orcid.org/0000-0003-3340-4223
장준(Chang, Joon) ORCID logo https://orcid.org/0000-0003-4542-6841
정지예(Jung, Ji Ye) ORCID logo https://orcid.org/0000-0003-1589-4142
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/154378
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse